Akari Therapeutics, PLC (AKTX)
Stock Price:
$1.57 USD
-0.03 (-1.88%)
Updated December 1, 4:00 PM EST - Market closed
After-hours: $1.63 +0.06 (3.82%) Dec 1, 4:08 PM
Key Info
| Market Cap |
24.90M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-17.11M |
| Shares Out |
15.86M |
| EPS (ttm) |
-0.97 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 1 |
| Last Price |
$1.57 |
| Previous Close |
$1.60 |
| Change ($) |
-0.03 |
| Change (%) |
-1.88% |
| Day's Open |
1.58 |
| Day's Range |
1.52 - 1.62 |
| Day's Volume |
119,439 |
| 52-Week Range |
1.06 - 2.61 |
More Stats
| Market Cap |
24.90M |
| Enterprise Value |
19.16M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
15.86M |
| Float |
n/a |
| EPS (basic) |
-0.10 |
| EPS (diluted) |
-0.97 |
| FCF / Share |
-0.07 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
66,825 |
| Short Ratio |
0.43 |
| Short % of Float |
n/a |
| Beta |
1.64 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
18.09 |
| Revenue |
n/a |
| Operating Income |
-16.94M |
| Net Income |
-17.11M |
| Free Cash Flow |
-12.92M |
| Net Cash |
5.73M |
| Net Cash / Share |
0.36 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-133.16% |
| ROE |
-2,252.25% |
| ROIC |
328.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
5.00
Current: $1.57
High
5.00
Target: 5.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -16.94 | -19.97 | -37.77 | -27.25 | -30.58 | -1.92 | -3.61 | -3.67 | -2.25 | -0.79 |
| Net Income | -17.11 | -16.47 | -35.40 | -18.14 | -45.32 | -1.95 | -3.62 | -4.27 | -2.12 | -0.68 |
| Shares Outstanding | 1,831 | 1,540 | 1,247 | 1,178 | 852 | 85.52 | 21.08 | 12.46 | 11.92 | 11.42 |
| Earnings Per Share | -0.10 | -0.10 | -0.30 | -0.20 | -0.50 | -0.20 | -1.70 | -3.50 | -1.80 | -0.60 |
| Operating Cash Flow | -12.92 | -22.58 | -31.60 | -24.62 | -4.97 | -1.48 | -5.45 | -2.13 | -1.01 | -0.37 |
| Capital Expenditures | - | - | -0.04 | -0.05 | -0.01 | - | - | - | - | - |
| Free Cash Flow | -12.92 | -22.58 | -31.64 | -24.68 | -4.98 | -1.48 | -5.45 | -2.13 | -1.01 | -0.37 |
| Cash & Equivalents | 5.73 | 5.97 | 28.25 | 44.26 | 69.06 | 3.33 | 7.66 | 1.10 | 0.01 | - |
| Total Debt | - | - | - | - | - | 0.53 | - | 0.90 | - | - |
| Net Cash / Debt | 5.73 | 5.97 | 28.25 | 44.26 | 69.06 | 2.79 | 7.66 | 0.21 | 0.01 | - |
| Assets | 6.80 | 8.03 | 29.05 | 45.87 | 69.89 | 3.39 | 7.83 | 1.12 | 0.03 | - |
| Liabilities | 8.57 | 4.92 | 11.90 | 11.77 | 21.17 | 1.17 | 2.02 | 4.48 | 2.51 | - |
| Book Value | -1.77 | 3.11 | 17.15 | 34.10 | 48.72 | 2.22 | 5.81 | -3.36 | -2.49 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Akari Therapeutics, PLC |
| Country |
United Kingdom |
| Employees |
10 |
| CEO |
Clive Stuart Richardson |
Stock Information
| Ticker Symbol |
AKTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: AKTX |
Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.